Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.41 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.40 |
| ▸ | ALPI | P09923 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 3/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16801822 | 1.00 | KDM4E (0.51) | KDM4EHIF1ATDP1SLC1A3SLC1A2 | |
| SCHEMBL31520048 | 1.00 | KDM4E (0.51) | KDM4EHIF1ATDP1SLC1A3SLC1A2 | |
| SCHEMBL29934103 | 1.00 | KDM4E (0.51) | KDM4EHIF1ATDP1SLC1A3SLC1A2 | |
| SCHEMBL31520056 | 1.00 | KDM4E (0.51) | KDM4EHIF1ATDP1SLC1A3SLC1A2 | |
| SCHEMBL145723 | 1.00 | KDM4E (0.51) | KDM4EHIF1ATDP1SLC1A3SLC1A2 | |
| SCHEMBL17623477 | 0.84 | RXFP1 (0.39) | KDM4EHIF1ATDP1PKMCASR | |
| SCHEMBL20340876 | 0.84 | RXFP1 (0.39) | KDM4EHIF1ATDP1PKMRXFP1 | |
| SCHEMBL24380208 | 0.82 | KDM4E (0.54) | KDM4EHIF1ATDP1SLC1A3SLC1A2 | |
| SCHEMBL19273914 | 0.82 | KDM4E (0.54) | KDM4EHIF1ATDP1SLC1A3SLC1A2 | |
| SCHEMBL31469728 | 0.82 | KDM4E (0.54) | KDM4EHIF1ATDP1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1590 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098007-A1 | Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light | SOLIOME INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-3831379-B1 | A COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE AND/OR TRYPTOPHAN FOR POSITIVELY INFLUENCING THE INTESTINAL MICROBIOTA | CONARIS RES INSTITUTE AG (DE) | 2025-09-10 | — | — | EP | claimed |
| EP-4587007-A2 | COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT | Soliome, Inc. (US) | 2025-07-23 | — | — | EP | claimed |
| US-20250213549-A1 | COMPOSITION COMPRISING NICOTINAMIDE, NICOTINAMIDE PRECURSORS, NICOTINAMIDE METABOLITES OR COMBINATIONS THEREOF FOR PREVENTING OR REDUCING ONE OR MORE POST-ACUTE SYMPTOMS OF INFECTIOUS DISEASES | CONARIS RESEARCH INSTITUTE AG (DE) | 2025-07-03 | — | — | US | claimed |
| EP-4572737-A1 | METHODS OF USING A SMALL MOLECULE CHEMICAL COMPOUND TO REDUCE THE APPEARANCE OF RHYTIDS AND WRINKLES | Birchbiomed Inc. (CA) | 2025-06-25 | — | — | EP | claimed |
| CN-119894495-A | Method for reducing wrinkle and crease appearance using small molecule compounds | 伯奇生物医药有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-116087353-B | Metabolic identification method for wild cordyceps sinensis and substitute thereof | 武汉大学中南医院 | 2025-04-08 | — | — | CN | claimed |
| CN-114938659-B | Cardiovascular disease onset risk assessment marker based on metabonomics data and application thereof | 中国医学科学院阜外医院 | 2025-03-04 | — | — | CN | claimed |
| CN-119391580-A | Lactobacillus rhamnosus capable of preventing or treating inflammatory bowel disease and promoting digestion and application thereof | 内蒙古科拓生物有限公司 | 2025-02-07 | — | — | CN | claimed |
| EP-4499059-A1 | COMPOSITION COMPRISING NICOTINAMIDE, NICOTINAMIDE PRECURSORS, NICOTINAMIDE METABOLITES OR COMBINATIONS THEREOF FOR PREVENTING OR REDUCING ONE OR MORE POST-ACUTE SYMPTOMS OF INFECTIOUS DISEASES | CONARIS research institute AG (DE) | 2025-02-05 | — | — | EP | claimed |
| WO-2016038011-A1 | METHODS & COMPOUNDS USEFUL IN HEMATOPOIETIC STEM CELL MEDICINE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2016-03-17 | — | — | WO | claimed |
| EP-2995948-A1 | Methods and compounds useful in hematopoietic stem cell medicine | Ecole Polytechnique Federale de Lausanne (EPFL) (CH) | 2016-03-16 | — | — | EP | claimed |
| WO-2016013017-A1 | EX-VIVO INDUCED REGULATORY MESENCHYMAL STEM CELLS OR MYELOID-DERIVED SUPPRESSOR CELLS AS IMMUNE MODULATORS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD (IL) | 2016-01-28 | — | — | WO | claimed |
| WO-2015091862-A1 | SCREENING METHOD | IOMET PHARMA LTD (GB) | 2015-06-25 | — | — | WO | claimed |
| US-20140065099-A1 | Methods of Treating Mitochondrial Dysfunction | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2014-03-06 | — | — | US | claimed |
| WO-2012114204-A2 | METHODS OF TREATING MITOCHONDRIAL DYSFUNCTION | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) EPFL-TTO (CH) | 2012-08-30 | — | — | WO | claimed |
| US-20100261774-A1 | Methods for the modulation of Leishmania major infection in mammals | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2010-10-14 | — | — | US | claimed |
| US-20090208565-A1 | STABILIZED EXENDIN-4 COMPOUNDS | ZEALAND PHARMA A/S (DK) | 2009-08-20 | — | — | US | claimed |
| US-20060194719-A1 | Stabilized exendin-4 compounds | ZEALAND PHARMA A/S (DK) | 2006-08-31 | — | — | US | claimed |
| EP-1369114-A1 | Use of tryptophan metabolites as pharmaceutical agents | Terness, Peter, Priv. Doz. Dr. (DE) | 2003-12-10 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098007-A1 | Compounds and Their Use in Filtering Ultraviolet and/or High-Energy Visible Light | UGT8, UGT1A3, FUT5 | KDM4E 3137/4885HIF1A 3431/4885TDP1 1560/4885 |
| US-20060194719-A1 | Stabilized exendin-4 compounds | GLP1R, IAPP, MC4R | KDM4E 626/4885HIF1A 2894/4885TDP1 4193/4885 |
| US-20090208565-A1 | STABILIZED EXENDIN-4 COMPOUNDS | GLP1R, IAPP, MC4R | KDM4E 610/4885HIF1A 2857/4885TDP1 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.